THE DEFINITIVE GUIDE TO API PHARMACEUTICAL

“The existing circumstance has exposed some structural weaknesses while in the EU’s medicines offer chain and a large dependence on non-EU international locations for active pharmaceutical ingredients,” Kyriakides explained. She advised that supply chain challenges be addressed within an EU pharmaceutical technique envisioned to get released